Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Ontology highlight
ABSTRACT: The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.
DISEASE(S): Esophageal Neoplasms,Biliary Tract Neoplasms,Colorectal Neoplasms,Carcinoma, Hepatocellular,Endometrial Neoplasms,Hcc, Non-microsatellite Instability-high (msi-h)/ Deficient Mismatch Repair (dmmr) Crc, Pdac, And Btc,Neoplasms,Pancreatic Ductal Adenocarcinoma
PROVIDER: 2384436 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA